selectION Therapeutics
Phase 2selectION Therapeutics' si-544 is a first-in-class Kv1.3 blocker and the first disease modifying treatment for T cell autoimmunity. Autoimmunity affects millions worldwide, but current treatments leave the root cause untouched. si-544 is the first therapy to safely and selectively deactivate disease-causing T cells, while preserving immune competence.
About
selectION Therapeutics' si-544 is a first-in-class Kv1.3 blocker and the first disease modifying treatment for T cell autoimmunity. Autoimmunity affects millions worldwide, but current treatments leave the root cause untouched. si-544 is the first therapy to safely and selectively deactivate disease-causing T cells, while preserving immune competence.
Funding History
2Total raised: $18.2M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile